OBJECTIVES:  Better dementia-care quality measurement is needed. Unfortunately, measure development is time consuming and expensive. Using the NQF Measure Incubator at OptumLabs^TM, the feasibility of evaluating medication-use measures for persons with dementia was examined. It was hypothesized that trends in measure rates over time would correspond to program implementation and rates vary based upon how explicitly specifications define populations. METHODS:  For two existing measures (antipsychotic and anticholinergic/TCA use), annual rates were calculated, 2001-2015, using the OptumLabs Data Warehouse, which includes over 150 million nationally representative commercial and Medicare Advantage (MA) enrollees. Dementia cases were identified using specifications based on NQF #2111. Subgroup analyses were performed based on age, race, gender, geographic region, and insurance type. Sensitivity analyses were conducted on eligibility criteria based on number of header diagnoses and psychoses exclusions specified. RESULTS:  Antipsychotic use in persons with dementia was 13-18% from 2001-2006. In 2007, the rate dropped to 16% and continued to decline, remaining somewhat constant at 13-15% up to 2015. Stratifying by insurance, MA enrollees had higher rates than commercial. Rates were higher amongst those ≥65y.o.a. Cases <65y.o.a. had increasing rates from 7% in 2001 to up to 20% in 2015. Differences were not seen by race or geographic region. Similar results were noted for anticholinergic/TCA use. Case identification was not sensitive to the number of header diagnoses used. Rates varied by ~1-2% difference based on header diagnosis number. For NQF #2111, results did not differ based on denominator psychoses exclusions. CONCLUSIONS:  The Measure Incubator provides efficiency in quality measure development and assessment. Leveraging this resource allowed for examination and modification of specifications for two dementia-specific care quality measures within a relatively short timeframe at relatively low cost. Measures can be tested and adapted efficiently with this resource. Additional work is needed to understand clinical implications.